DBV Technologies reported $-17287000 in Net Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
DBV Technologies DBVT:US USD -17287000 5.75M
Acadia Pharmaceuticals ACAD:US USD -27183000 6.83M
Alnylam Pharmaceuticals ALNY:US USD -405920000 128.52M
Amarin AMRN:US USD -5140000 64.82M
Biocryst Pharmaceuticals BCRX:US USD -42520000 16.34M
Biomarin Pharmaceutical BMRN:US USD -6652000 34.32M
Esperion Therapeutics ESPR:US USD -55117000 11.21M
Galectin Therapeutics GALT:US USD -8597000 1.02M
Halozyme Therapeutics HALO:US USD 61.63M 38.95M
Insmed INSM:US USD -131145000 35.5M
Intercept Pharmaceuticals ICPT:US USD 267.45M 274.98M
Neurocrine Biosciences NBIX:US USD 68.5M 85.4M
Ptc Therapeutics PTCT:US USD -109315000 42.77M
Sarepta Therapeutics SRPT:US USD -257738000 26.26M
Ultragenyx Pharmaceutical RARE:US USD -245106000 86.94M
United Therapeutics UTHR:US USD 239.3M 123.3M
YTE INCY:US USD 112.78M 48.66M